PINNED
PINNED
Streamlining Biomanufacturing of Personalised Cancer Immunotherapies with Synthetic DNA
13 October 2025 | By
A Synthetic DNA Approach for Speed, Scale & Flexibility
List view / Grid view
Articles
The relevance of homogeneous radiometric assays in modern drug discovery
In the past two decades, several alternative, non-radiometric assay formats have been developed for the high-throughput screening (HTS) of target classes such as protein kinases, which were previously screened using radiometric assays. Radiometric screening (and the expertise to perform such HTS) has thus declined in recent years...
Finding a cure for neglected tropical diseases with cell-based assays
Neglected tropical diseases pose a significant threat to public health and affect nearly one billion people in tropical and sub-tropical regions throughout the world. There is a pressing need to identify new therapeutics for NTDs and many developed nations are participating in drug discovery efforts...
The challenges with antibody-based targeting of VEGF
Antibody-based targeting of vascular endothelial growth factor (VEGF) is a highly successful and widely-used clinical treatment for angiogenesis-related diseases. Currently, bevacizumab (Avastin; Genentech) and ranibizumab (Lucentis; Genentech/Roche) are the leading antibody drugs for targeting VEGF...
Wanted: Zika virus researchers
10 February 2016 | By Victoria White, Digital Content Producer, Drug Target Review
The MRC has launched a £1m rapid response funding initiative to better understand the nature of the risk posed by the Zika virus. Find out about this initiative and NIH's call for research here...
canSAR: a portal to Big Data for drug discovery
9 February 2016 | By Dr Bissan Al-Lazikani and Elizabeth Coker, The Institute of Cancer Research, London
Dr Bissan Al-Lazikani and Elizabeth Coker discuss canSAR: the first public domain example of Big Data for drug discovery...
Antibody fragment technology and avian IgY antibodies: a powerful combination
Recombinant monoclonal antibodies or antibody biologics have been successfully developed as diagnostic and therapeutic agents...
Zika Virus: a public emergency of international concern
4 February 2016 | By Victoria White, Digital Content Producer, Drug Target Review
The Zika virus has taken hold in South America. Its possible link to microcephaly in newborn babies and neurological conditions has led the World Health Organization to declare a Public Health Emergency of International Concern. Here we discuss the virus, countermeasures and the race for a vaccine...
Drug Target Review’s top 10 stories from 2015
28 January 2016 | By Victoria White, Digital Content Producer, Drug Target Review
2015 was an exciting year for the drug discovery industry. Here we look at a selection of stories that particularly stood out for us…
Analysing recombinant proteins by mass spectrometry
The drug discovery landscape is changing: no longer limited to big pharma, it is now within reach of academics and small consortia alike. Regardless of the setting, drug discovery requirements are always the same: strong biological theory, good chemical starting material and high quality protein samples from which to determine…
Mass spectrometry and systems biology approaches in drug target discovery
Cells, organs and organisms are complex biological systems consisting of inter-related components that co-operatively work to maintain function and respond to change. Malfunction of any component can lead to pathologies and disease, leading to system-wide changes and subsequent adaptation. Hence, the ability to study and predict system behaviour will considerably…
Drug Target Review – Issue #4 2015
3 December 2015 | By Drug Target Review
Included in this issue: Biomarkers, Mass Spectrometry, Target Validation, Drug Development, Personalised Medicines, Next-Generation Sequencing, Protein Expression, Companion Diagnostics, and much more...
Mass Spectrometry In-Depth Focus 2015
In this Mass Spectrometry In-Depth Focus: Michelle M. Hill from University of Queensland discusses Mass spectrometric and systems biology approaches in drug target discovery, and Nicola Burgess-Brown, Rod Chalk, Claire Strain-Damerell and Pravin Mahajan from the Structural Genomics Consortium look at analysing recombinant proteins by mass spectrometry...
Health and Safety Law – Avoid falling off a ladder and into the dock
Health and Safety Law rarely arouses interest, either amongst companies or lawyers, yet its importance is growing and it has become the area in which companies and their directors are likely to find themselves in the dock, facing a criminal prosecution.
Biomarkers as molecular footprints for cancer therapy: current perspectives and promises
Knowledge about cancer biomarkers has increased tremendously and provides clinicians and researchers with valued opportunities to understand the molecular mechanism of cancer, thus applying it to effective, early-stage diagnosis and treatment. Cancer biomarkers include a vast range of biochemical molecules such as nucleic acids, proteins, sugars, lipids, small metabolites, cytogenetic…
The challenges associated with ‘de-risking’ early-stage therapeutic targets
The pharmaceutical industry is searching for novel drug targets that could produce the next generation of ‘first-in-class’ therapeutic agents. The challenge for academia is to identify and translate such targets and to provide starting points and confidence in the underlying science. The aim should be to generate evidence that modulation…
